Back to Search
Start Over
Supplementary Figure S1. Study 20120148 - Hematological relapse-free survival for patients in CR1 by MRD level at baseline after at least 3 intensive chemotherapy blocks from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- RFS by baseline MRD level from Study 20120148
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....39411af126f6f2d40456d9d1f9609510
- Full Text :
- https://doi.org/10.1158/1078-0432.22474200